APOL1 and kidney disorder: Currently, two APOL1 inhibitors, i.e., VX-147 [125] and the antisense oligonucleotide AZD2373 are being tested in Phase 2 (NCT04340362) and Phase 1 (NCT04269031) clinical trials, respectively, for the treatment of patients with APOL1-associated kidney disease.